Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Wenting Du

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6765-0129; OpenAlex author ID A5040436477. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 3 papers · 2020: none · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 2 papers

Papers 12

  1. KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-23-1421↗
  2. Notch Signaling Regulates Immunosuppressive Tumor-Associated Macrophage Function in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-23-0037↗
  3. WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer. Co-author DOI 10.1084/jem.20220503↗
  4. Arginase 1 is a key driver of immune suppression in pancreatic cancer. Co-author DOI 10.7554/elife.80721↗
  5. AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-20-0860↗
  6. Therapeutic Potential of Targeting Stromal Crosstalk-Mediated Immune Suppression in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.682217↗
  7. Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer. Co-author DOI 10.1172/jci.insight.126117↗
  8. Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. Co-author DOI 10.1172/jci.insight.129212↗
  9. Targeting TGFβR2-mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer. Co-author DOI 10.15252/emmm.201910515↗
  10. Does Axl have potential as a therapeutic target in pancreatic cancer? Co-author DOI 10.1080/14728222.2018.1527315↗
  11. Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-17-1973↗
  12. Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-16-0834↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marina Pasca di Magliano · 5 shared papers, 2021–2024 · strength 0.83
  2. Rolf A. Brekken · 7 shared papers, 2017–2021 · strength 0.73
  3. Eileen S. Carpenter · 4 shared papers, 2023–2024 · strength 0.61
  4. Katelyn L. Donahue · 4 shared papers, 2023–2024 · strength 0.61
  5. Rosa Elena Menjivar · 3 shared papers, 2023–2024 · strength 0.48
  6. Filip Bednar · 3 shared papers, 2023–2024 · strength 0.45
  7. Padma Kadiyala · 3 shared papers, 2023–2024 · strength 0.44
  8. Yaqing Zhang · 2 shared papers, 2021–2023 · strength 0.36
  9. Huocong Huang · 4 shared papers, 2017–2021 · strength 0.36
  10. Yaqing Zhang · 2 shared papers, 2023–2024 · strength 0.34
  11. Samantha B. Kemp · 2 shared papers, 2024 · strength 0.31
  12. Nina G. Steele · 2 shared papers, 2024 · strength 0.31
  13. Zeribe C. Nwosu · 2 shared papers, 2023–2024 · strength 0.27
  14. Victoria H. Cruz · 2 shared papers, 2018–2019 · strength 0.20
  15. William Reece Burns · 1 shared paper, 2024 · strength 0.18
  16. Wei Yan · 1 shared paper, 2024 · strength 0.18
  17. Abdel Nasser Hosein · 2 shared papers, 2019 · strength 0.17
  18. Anirban Maitra · 2 shared papers, 2018–2019 · strength 0.17
  19. Christopher J. Halbrook · 1 shared paper, 2023 · strength 0.14
  20. Daniel James Salas-Escabillas · 1 shared paper, 2023 · strength 0.14
  21. Allison Bischoff · 1 shared paper, 2023 · strength 0.14
  22. Costas Andreas Lyssiotis · 1 shared paper, 2023 · strength 0.14
  23. Howard C. Crawford · 1 shared paper, 2023 · strength 0.14
  24. Moriah M. Hagopian · 2 shared papers, 2017–2019 · strength 0.14
  25. Rémy Nicolle · 1 shared paper, 2024 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.